O-010: VOLTAGE: Investigator-Initiated Clinical Trial of Nivolumab Monotherapy and Subsequent Radical Surgery Following Preoperative Chemoradiotherapy in Patients with Microsatellite Stable Locally Advanced Rectal Cancer
Takayuki Yoshino, et al.

A promising pCR rate of 30%, with mild toxicity, was shown in MSS LARC pts treated with nivo plus radical surgery. PD-L1 expression and elevated CD8/T reg ratio may be better predictors of nivo benefit, warranting further study in a larger cohort. 

O-011: Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12
Ralf-Dieter Hofheinz, et al.

Upfront CRT followed by consolidation CT was feasible, resulted in better compliance to CRT but worse compliance to CT compared to group A. Long term follow-up is required to assess if improved pCR in arm B translate to better oncological outcome.